Fig. 5

Sptbn2 mediates Mettl1-induced neurogenesis. (A, B) Western blotting and RT-qPCR of Sptbn2 to validate the knockdown efficiency in NSCs. **P < 0.01, ***P < 0.001 compared with Vector. (C-F) Immunofluorescence staining and quantification for Tuj1, GFAP, and EdU on NSCs treated with overexpressing Mettl1 or shRNA Sptbn2. Scale bar, 200 μm. n = 3, *P < 0.05, **P < 0.01 compared with Mettl1 overexpression. (G, H) Western blotting and RT-qPCR of Sptbn2 to confirm the overexpression efficiency in NSCs. **P < 0.01 compared with Vector. (I-L) Immunofluorescence staining and quantification for Tuj1, GFAP, and EdU on NSCs treated with shRNA Mettl1 or overexpressing Sptbn2. Scale bar, 200 μm. n = 3, **P < 0.01, ***P < 0.001 compared with shRNA Mettl1. Data are represented as the mean ± SEM. Sh-Mettl1, shRNA Mettl1; Sh-Sptbn2, shRNA Sptbn2; OE-Mettl1, overexpressing Mettl1; OE-Sptbn2, overexpressing Sptbn2; n represents number of independent experiments